SAVA Cassava Sciences Inc.

1.28
+0.01  (+1%)
Previous Close 1.27
Open 1.27
Price To Book 1.27
Market Cap 22,040,704
Shares 17,219,300
Volume 37,428
Short Ratio
Av. Daily Volume 85,164
Stock charts supplied by TradingView

NewsSee all news

  1. Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

    - Phase 2a Study Showed Statistically Significant Decreases (p<0.001) in Clinical Biomarkers of Alzheimer's Disease - - Phase 2b Study in Patients with Alzheimer's Disease Initiated in Multiple Clinical Sites - -

  2. Cassava Sciences' Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2019

    AUSTIN, Texas, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that clinical results of its Phase 2a

  3. Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer's Patients

    First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

  4. Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer's Patients

    Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p<.001) Clinical data support initiation of a Phase 2b study in Alzheimer's in Q3

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a data to be presented at CTAD December 5, 2019 at 8:15 a.m. PT. Phase 2b data due 4Q 2020.
PTI-125
Alzheimer’s disease

Latest News

  1. Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

    - Phase 2a Study Showed Statistically Significant Decreases (p<0.001) in Clinical Biomarkers of Alzheimer's Disease - - Phase 2b Study in Patients with Alzheimer's Disease Initiated in Multiple Clinical Sites - -

  2. Cassava Sciences' Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2019

    AUSTIN, Texas, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that clinical results of its Phase 2a

  3. Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer's Patients

    First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

  4. Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer's Patients

    Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p<.001) Clinical data support initiation of a Phase 2b study in Alzheimer's in Q3